Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Prostate cancer breakthrough as scientists invent new ultra-accurate non-invasive test for the killer disease
Prostate cancer breakthrough as scientists invent new ultra-accurate non-invasive test for the killer disease
UK scientists have made a breakthrough in prostate cancer research with a new test that could make spotting the killer disease much easier.
FDA declines to approve Pfizer biosimilar of Roche's cancer drug
FDA declines to approve Pfizer biosimilar of Roche's cancer drug
(Reuters) - Pfizer Inc said on Monday U.
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
CAMBRIDGE, Mass.
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.
Shire rejects £43bn offer from Japan's Takeda
Shire rejects £43bn offer from Japan's Takeda
Japan's Takeda Pharmaceutical is in talks with Shire after making a £43bn bid for the London-listed rare diseases drug maker.
Biogen boosts investment in neurology with $1 billion Ionis deal
Biogen boosts investment in neurology with $1 billion Ionis deal
(Reuters) - Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company’s potential blockbuster dr...
GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval
GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval
(Reuters) - An advisory panel to the U.
New Report Shows Over 500 Medicines in Development For Neurological Disorders
New Report Shows Over 500 Medicines in Development For Neurological Disorders
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.
P&G to acquire German Merck's consumer health business for about $4.21 billion
P&G to acquire German Merck's consumer health business for about $4.21 billion
Procter & Gamble has agreed to acquire Merck KGaA's consumer health unit for 3.
Allergan's Interest Raises Stakes in Pursuit of Drugmaker Shire
Allergan's Interest Raises Stakes in Pursuit of Drugmaker Shire
Allergan Plc’s potential offer for Shire Plc may start a bidding war with Takeda Pharmaceutical Co.
Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
SOUTH SAN FRANCISCO, Calif.
FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
The U.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand